Physician profile
Reena Khetpal
NPI 1073005781
$2,727.95
in general payments reported to CMS, 2019-2025
18 companies · $541 in 2025
The $541 reported for 2025 was more than what 90% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $379 · 2023: $1,072 · 2024: $736 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,348.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $561.22 | 2022-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $426.99 | 2022-2025 | |
| Pfizer INC. | $373.62 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $340.54 | 2022-2024 | Xarelto |
| Abbvie INC. | $339.26 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.86 | 2022-2025 | Xifaxan |
| Paratek Pharmaceuticals, INC. | $109.28 | 2022-2024 | Nuzyra |
| Electromed, INC. | $108.95 | 2022-2024 | Smartvest |
| Gilead Sciences, INC. | $60.84 | 2023 | Veklury |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.49 | 2023-2024 | Lifevest |
| Insmed, INC. | $43.22 | 2023 | Arikayce |
| Novo Nordisk INC | $38.52 | 2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $25.20 | 2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $24.86 | 2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $21.49 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $21.45 | 2023 | Fetroja |
| Kestra Medical Technology Services, INC. | $18.99 | 2024 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $18.17 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Khetpal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.